European Pharmaceutical Review

APRIL 10, 2025

In the EU, a joint PFAS Restriction Proposal under REACH was submitted, aiming for a full ban by 2028/2030. billion Global concerns surrounding PFAS, or per- and polyfluoroalkyl substances, are due to their well-documented effects on human health and the environment. There is worldwide concern around the use of PFAS.

Packaging 59

Packaging Documentation Communication 59

The Checkup by Singlecare

DECEMBER 12, 2024

Addyi is currently only available as a brand-name drug , but a generic Addyi may be available after 2028. Plans may have criteria to be met to offer coverage, including specific documentation from the provider to confirm the patient is pre-menopausal with a diagnosis of HSDD. Is Addyi covered by insurance?

Insurance 52

Insurance Insurance Coverage Documentation FDA 52

Pharmaceutical Technology

APRIL 27, 2023

billion by 2028. Regulatory documentation including a materials traceability report is provided and an extractables report is available upon request. Genomic medicine development was ranked as the top industry trend for 2023 in a survey of 198 GlobalData Pharma clients and prospects conducted between October and November 2022.

Vaccines 52

Vaccines Documentation Communication 52